New Delhi:

新德里：

Mankind Pharma

人类制药公司

, India's fourth largest drug firm by share, is gearing up to be among the first movers in India's

印度第四大制药公司，正在准备成为印度首批行动者之一。

semaglutide

司美格鲁肽

market, following the drug's patent expiry this month.

市场，本月该药物的专利到期后。

While India remains its immediate priority, international markets will be explored over time, Rajeev Juneja, vice chairman and managing director of Mankind Pharma told ET.

印度仍然是其当务之急，不过曼金药业公司的副董事长兼总经理拉吉夫·容贾告诉《经济时报》，国际市场也会随着时间的推移而逐步开拓。

He said the opportunity is substantial as obesity is a growing health crisis and semaglutide's relevance spans multiple specialties including cardiology, orthopaedics, and gynaecology.

他说，这一机会非常重要，因为肥胖问题日益成为一场健康危机，而司美鲁肽的相关性横跨多个专科，包括心脏病学、骨科和妇科学。

Read more:

阅读更多：

Weight-loss drug boom: Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?

减肥药热潮：更便宜的Ozempic仿制药会撼动印度的健身与营养行业吗？

The company plans to lead this charge independently with no plans to enter into any co-marketing or partnership arrangements with third parties.

公司计划独立领导这一行动，不打算与第三方进行任何联合营销或合作伙伴关系安排。

Live Events

现场活动

'We are preparing to participate in this segment and expect to be among the first wave of launches. Our approach remains disciplined, with a strong focus on quality, accessibility, and long-term value creation,' Juneja said.

“我们正准备参与这一领域，并期望成为首批上市的公司之一。我们的方法依然严谨，重点关注质量、可访问性和长期价值创造，”Juneja 表示。

Known for introducing drugs at 'affordable prices', Juneja said they are 'evaluating it (price) carefully'.

以“价格实惠”著称的琼杰表示，他们“正在仔细评估（价格）”。

'Our philosophy has always been to improve access to high-quality therapies for patients. Pricing is a strategic decision, and we are evaluating it carefully to ensure both accessibility and long- term sustainability,' he said.

“我们的理念一直是提高患者获得高质量治疗的机会。定价是一个战略性决策，我们正在仔细评估，以确保既能实现可及性，又能保证长期可持续性，”他说道。

Read more:

阅读更多：

Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market share

诺和诺德的“司美格鲁肽”在与礼来争夺市场份额的较量中占据上风

While India will remain their immediate focus, international markets will be explored over time, he said. 'With our strong doctor relationships and extensive reach across metro and non-metro markets, we are well positioned to support patient access across the country,' he said.

他说，虽然印度仍将是他们短期内关注的焦点，但国际市场也会随着时间的推移逐步开拓。“凭借我们与医生的紧密联系以及在大都市和非大都市市场的广泛覆盖，我们有能力在全国范围内支持患者获得医疗服务。”

Juneja said Mankind's diabetes portfolio ranks among the top 5 in the therapy area, consistently outperforming the Indian Pharmaceutical Market (IPM), with chronic therapies forming an increasingly core part of their business mix. This strong foundation positions them well to expand into semaglutide.

Juneja表示，Mankind的糖尿病产品组合在治疗领域排名前五，持续超越印度制药市场（IPM），慢性治疗日益成为其业务组合的核心部分。这一坚实的基础使他们能够很好地扩展到司美鲁肽领域。

'We believe our experience in diabetes and chronic care positions us well to responsibly scale this therapy once it is introduced.'.

“我们相信，我们在糖尿病和慢性病护理方面的经验，使我们能够很好地负责任地推广这种疗法，一旦它被引入。”

With the patent set to expire on March 20, nearly 50 generic brands are set to enter the market, expanding the reach of new class of medicines even as the prices are expected to see a significant drop.

随着该专利将于 3 月 20 日到期，近 50 种仿制药品牌准备进入市场，在价格预计将大幅下降的同时，扩大了新一类药物的覆盖范围。

Juneja says he sees a 'very large' and 'fast-growing opportunity' as semaglutide's relevance extends beyond diabetes, spanning multiple specialities including cardiology, orthopaedics and gynaecology.

Juneja 表示，随着司美鲁肽的相关性从糖尿病扩展到包括心脏病学、骨科和妇科学在内的多个专科，他看到了一个“非常大”且“快速增长的机会”。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)